Middle East and Africa Pharmaceutical Fill and Finish Outsourcing Market

Market Introduction

The pharmaceutical fill and finish outsourcing are more inclined towards contract manufacturing. There are several types of contract manufacturing for pharmaceuticals as well as for biotechnology products that involve partial contract manufacturing and complete manufacturing of pharmaceuticals and biotechnology products.

Moreover, the increase in demand for biopharmaceutical drugs, growing clinical developments, and development of biologics and biosimilars is driving the market’s growth. However, complex processes and high cost of production critically impacts the growth of the market.

With the onset of pandemic, the demand for contract manufacturers accelerated. For instance, GCC companies are looking to compete in contract manufacturing. For example, with around 30 pharmaceutical companies, the GCC pharmaceutical industry is still evolving and is currently dominated by Saudi Arabia accounting to 65% of the GCC pharmaceutical market share. Furthermore, Ahramonline report states that, the Egyptian Drug Authority (EDA) has activated a package of incentive measures for contract manufacturing pharmaceuticals and medical supplies for opening new markets and increase the export value of Egyptian pharmaceutical products and increase incentive for pharmaceutical investment. Moreover, four pharmaceutical companies have applied for contract manufacturing in 2019 and 2020, and 57 products have been approved for export to Sudan, Saudi Arabia, Cyprus, and Yemen.

Market Overview and Dynamics

The Middle East & Africa pharmaceutical fill and finish outsourcing market is expected to reach US$ 79.4 million by 2028 from US$ 60.0 million in 2021. The market is estimated to grow at a CAGR of 4.1% from 2021–2028. Pharmaceutical drug manufacturers collaborate with contract service providers to leverage their experience and expertise in the latest fill finish technologies. Currently, over 115 companies are actively providing services for the fill finish of biologics. Many service providers have also acquired other players in the recent past to enhance their service offerings. For instance, Sanofi has outsourced the manufacturing of its biologics to Boehringer Ingelheim. Moreover, AbbVie operations have successfully developed and delivered drug products for more than 130 years; over 14 million small-volume parenteral (SVPs) are filled annually across AbbVie’s network, and the filled products are distributed over 175 countries.

Key Market Segments

In terms of state of finished products, the liquid segment accounted for the largest share of the Middle East & Africa pharmaceutical fill and finish outsourcing market in 2020. In terms of content, the organic substances isolated from microorganism’s segment accounted for the largest share of the Middle East & Africa pharmaceutical fill and finish outsourcing market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the pharmaceutical fill and finish outsourcing market in Middle East & Africa are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott, TEVA PHARMACEUTICAL INDUSTRIES LTD, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd, Piramal Enterprises Ltd., Cytovance Biologics, Thermo Fisher Scientific Inc. (Patheon N.V), and Boehringer Ingelheim International GmbH.

Reasons to Buy Report

• To understand the Middle East & Africa pharmaceutical fill and finish outsourcing market landscape and identify market segments that are likely to guarantee a strong return
• To comprehend the ever-changing market landscape and stay ahead in competition
• To efficiently plan merger and acquisition, and partnership deals in the Middle East & Africa pharmaceutical fill and finish outsourcing market by identifying segments with the most promising probable sales
• To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
• To obtain market revenue forecast of the Middle East & Africa pharmaceutical fill and finish outsourcing market based on various segments for the period 2021–2028

MIDDLE EAST & AFRICA PHARMACEUTICAL FILL AND FINISH OUTSOURCING MARKET SEGMENTATION

By State of Finished Product

•             Solids

•          Semi-Liquid

•          Liquid

By Content

•             Organic Substances Isolated from Animal Origin

•          Organic Substances Isolated from Microorganisms

•          Inorganic Substances

By Country

• Middle East & Africa
• Saudi Arabia
• South Africa
• UAE
• Rest of Middle East & Africa

Companies Mentioned

• Abbott
• TEVA PHARMACEUTICAL INDUSTRIES LTD
• Dr. Reddy's Laboratories
• Sun Pharmaceutical Industries Ltd
• Piramal Enterprises Ltd.
• Cytovance Biologics
• Thermo Fisher Scientific Inc. (Patheon N.V)
• Boehringer Ingelheim International GmbH      

Middle East and Africa Pharmaceutical Fill and Finish Outsourcing Market Strategic Insights

Middle East and Africa Pharmaceutical Fill and Finish Outsourcing Market Segmentation Analysis

Middle East and Africa Pharmaceutical Fill and Finish Outsourcing Market Report Highlights

Middle East and Africa Pharmaceutical Fill and Finish Outsourcing Report Scope

Middle East and Africa Pharmaceutical Fill and Finish Outsourcing Market Country and Regional Insights